Dmytro Kharkov

Altimmune's IMPACT study data published in The Lancet

Altimmune's IMPACT study data published in The Lancet
@AltimmuneInc: Altimmune's IMPACT study results

Altimmune has announced that the 24-week data from their IMPACT Phase 2b study in patients with MASH has been published in The Lancet.

The study results, which mark a significant development in medical research, are also being presented as a late-breaking oral presentation at The Liver Meeting 2025 hosted by the American Association for the Study of Liver Diseases (AASLD). This study is a part of ongoing efforts to address liver-related health issues, highlighting the potential future impacts of Altimmune's research in the medical field.

Altimmune's latest findings build on its sustained focus within the liver disease and metabolic disorder landscape, reflecting themes explored in previous analyses of the evolving MASH landscape alongside industry experts. The company's steady progress, demonstrated by recent milestones such as the completion of enrollment for its Phase 2 AUD trial, underscores a broader commitment to advancing therapeutic options for complex liver conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.